ZyVersa Therapeutics- Units (1 Ord Share Class A & 3/4 War) Operating Income

ZyVersa Therapeutics- Units (1 Ord Share Class A & 3/4 War)'s operating income stands at $-25B as of March 2026. That compares with $-4.4B in the prior-year period — down 458.0% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

ZyVersa Therapeutics- Units (1 Ord Share Class A & 3/4 War) reported $-25B in operating income versus $-4.4B a year earlier — a 458.0% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $-4.4B in the prior-year period — down 458.0% year over year. Sustained growth in operating income can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how ZyVersa Therapeutics- Units (1 Ord Share Class A & 3/4 War)'s operating income evolved across reporting periods, while the comparison chart places LSPRU next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.